Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real‐world academic clinical practice: a Canadian multicentre retrospective study

Psoriasis is a chronic inflammatory condition for which biologic therapies have been proven as effective therapies.1 However, considerable variation in the real world efficacy of these agents is observed in clinical practice.2 Given the treatment choices available, it is vital that dermatologists have access to the necessary information for optimal treatment selection in daily clinical practice. In this large, multi-centre study, we examine the real world effectiveness of, etanercept (ETN), adalimumab (ADA), ustekinumab (UST), infliximab (IFX) and validated assessment tools of response to these treatments. This article is protected by copyright. All rights reserved.